In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage


QUESTION: In patients with cancer and venous thromboembolism (VTE), is a fixed dose of subcutaneous low molecular weight (LMW) heparin better than oral warfarin for secondary prophylaxis of VTE?

In patients with cancer and venous thromboembolism, subcutaneous enoxaparin and oral warfarin were equally effective for secondary prophylaxis of venous thromboembolism at 3 months. Patients who received enoxaparin had a lower rate of fatal haemorrhage than those who received warfarin.

Design
Randomised (allocation concealed*),†, blinded (outcome assessors and data analysts)‡,‡ controlled trial with primary follow up to 3 months.

Setting
25 centres in France.

Patients
146 patients > 18 years of age (mean age 66 y, 55% women) with cancer of any type and deep venous thrombosis and/or pulmonary embolism. Exclusion criteria were previous heparin induced thrombocytopenia, allergy to iodine, pregnancy, fibrinolytic treatment within 3 days, oral anticoagulant use for > 5 days, treatment with full dose heparin for this episode of VTE, major pulmonary embolism with shock, life expectancy < 3 months, contraindication to anticoagulants, severe hepatic failure, planned major surgery or planned chemotherapy known to induce thrombocytopenia within 3 months. 138 patients (95%) were included in the primary outcome analysis at 3 months.

Intervention
71 patients were allocated to a fixed dose of subcutaneous enoxaparin, 1.5 mg/kg body weight, once daily for 3 months. 75 patients were allocated to oral warfarin sodium, 6–10 mg, subsequently adjusted to achieve an international normalised ratio (INR) of 2.0–3.0 for 3 months.

Main outcome measures
Main outcome was treatment failure (symptomatic and objectively confirmed recurrent VTE and/or major bleeding at 3 mo). Secondary outcomes included major haemorrhage, fatal haemorrhage, mortality, and progression of underlying cancer.

Main results
The study was stopped prematurely because of slow patient accrual. Analysis was by intention to treat. At 3 months, patients in the enoxaparin and warfarin groups did not differ for treatment failure, major haemorrhage, mortality, or progression of underlying cancer (table). Patients in the enoxaparin group had a lower rate of fatal haemorrhage at 3 months (table). At 6 months, the groups did not differ for mortality or cancer progression.

Conclusions
In patients with cancer and venous thromboembolism, subcutaneous enoxaparin and oral warfarin were equally effective for secondary prophylaxis of venous thromboembolism.
In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage

Evid Based Med 2003 8: 85
doi: 10.1136/ebm.8.3.85

Updated information and services can be found at:
http://ebm.bmj.com/content/8/3/85

These include:

References
This article cites 4 articles, 1 of which you can access for free at:
http://ebm.bmj.com/content/8/3/85#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (754)
- Stroke (546)
- Pulmonary embolism (73)
- Venous thromboembolism (109)
- Chemotherapy (82)
- Epidemiologic studies (1092)
- Liver disease (55)
- Clinical trials (epidemiology) (1596)
- Eating disorders (15)
- Immunology (including allergy) (571)
- Pregnancy (333)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/